26 results about "Alcohol use disorder" patented technology

To provide a novel tetracycline derivative having reduced antimicrobial activity for use in treating disorders of the central nervous system.SOLUTION: Provided are novel molecules comprising a modified tetracycline molecule including Deamino Diacetyl Minocycline, Methyl Ether Minocycline, Ethyl Ether Minocycline, Propyl Ether Minocycline, Butyl Ether Minocycline, Butyl Ether Monoacetyl Minocycline, Butyl Ether Diacetyl Minocycline, Butyl Ether Triacetyl Minocycline, or Butyl Ether Tetra Acetyl Minocycline, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, and tautomers thereof, and methods for using the same to treat Alcohol Use Disorder (AUD), Substance Use Disorder (SUD), tobacco use, pain, or proinflammatory disorders.SELECTED DRAWING: None

The invention relates to application of an OIP5-AS1 gene in screening of alcohol use disorder, and belongs to the technical field of screening of alcohol use disorder. In order to solve the problem that an existing AUD screening method lacks a molecular marker related to genetic susceptibility and is difficult to realize early intervention and individualized prevention, the invention provides application of an OIP5-AS1 gene in alcohol use disorder screening, and particularly relates to application of the OIP5-AS1 gene in preparation of an alcohol use disorder screening kit. The OIP5-AS1 in a sample is amplified and detected through real-time fluorescent quantitative PCR (polymerase chain reaction) by taking plasma of a subject as a detection object, and if the relative expression quantity of the OIP5-AS1 gene reaches 1.53 threshold or above, the subject has genetic susceptibility to alcohol use disorder. The OIP5-AS1 gene as a marker can provide objective and quantifiable detection indexes, reflect individual genetic susceptibility and realize long-term risk prediction, and has important clinical application value.

The present disclosure relates to methods for treating subjects having a substance use disorder (SUD) with 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 negative allosteric modulators. Specifically, in some embodiments, this disclosure relates to methods of treating a subject having SUD who is at risk of relapse to alcohol use. In some embodiments, this disclosure relates to methods of promoting remission in a subject having SUD. In some embodiments, the SUD is alcohol use disorder (AUD), opioid use disorder (OUD), or a stimulant use disorder such as cocaine use disorder (CUD).

A method of treating opioid use disorder (OUD) or alcohol use disorder (AUD) includes administering a pharmaceutically effective amount of a topical composition comprising an anhydrous suspension including naltrexone to an oral cavity of a subject for oral absorption therein. The topical composition is formulated to self-emulsify in an aqueous environment of the oral cavity.

The invention discloses application of putrescine as a molecular marker in preparation of a reagent for evaluating the severity of alcohol use disorder. The reagent is used for detecting the content of putrescine in a sample. By detecting the putrescine content in the excrement sample of the tested person, the alcohol use disorder severity of the person can be evaluated, and the method has important clinical significance for formulating a better diagnosis and treatment scheme.

A combination therapy for use in treatment of substance abuse disorders, including alcohol use disorder (AUD) and opioid use disorder (OUD), includes both mitragynine (MG) and naltrexone (NTX). NTX is understood to be a mu opioid antagonist that is expected to block MG's analgesic effects. However, combining MG and NTX therefore results in a unique, unexpected, and beneficial treatment that decreases alcohol self-administration to a greater extent than either alone.

The invention discloses a prediction model for identifying alcohol use disorder and alcoholic hepatitis and application, a multi-dimensional identification model is constructed by integrating basic clinical information of a patient, intestinal bacterial community characteristics and an intestinal fungal flora structure, and the model is used for identifying alcohol use disorder and alcoholic hepatitis by means of conjoint analysis of intestinal micro-ecological flora (bacteria and fungi) and patient baseline data. A molecular marker combination scheme with innovativeness and practicability is provided for accurate differential diagnosis of AUD and AH.

Disclosed are method for predicting naltrexone response in subjects with AUD. In some embodiments, the methods include performing or having performed one or more methylation assays on a genomic DNA sample isolated from the subject to determine the methylation status of one or more regions of the isolated genomic DNA, wherein the one or more regions are subsequences of a gene selected from a mu opioid receptor (OPRM1) gene, a catechol-O-methyltransferase (COMT) gene, and a dopamine transporter (SLC6A3) gene, wherein the methylation status of the one or more regions of the isolated genomic DNA determined is predictive of naltrexone response in the subject. Also provided are method for treating patients diagnosed with AUD with the medication naltrexone based on a methylation status of a combination of specific methylation sites located associated with an OPRM1 gene, a COMT gene, and / or an SLC6A3 gene in obtained from each AUD patient.

The present invention relates to a method of treatment for chronic pain, opioid dependence, alcohol use disorder or autism using a class of pyrimidinone compounds, an adenylyl cyclase 1 (AC1) inhibitor. The invention described herein also pertains to pharmaceutical compositions and methods for treating diseases in mammals using those compounds disclosed herein.

Provided is an analytical method for providing information necessary for a diagnosis of alcohol use disorder, including measuring (i) an expression level of a gene encoding a JNK or p-JNK protein in a subject's sample, (ii) an expression level of a gene encoding a JNK or p-JNK protein and an expression level of a gene encoding the Elk-1 protein in a subject's sample, or (iii) expression levels of genes encoding JNK, p-JNK, and Elk-1 proteins in a subject's sample, respectively; and a kit for a diagnosis of alcohol use disorder which is used in the analytical method.

The present invention provides a dry powder formulation of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or excipients. The formulations described herein may be used to treat a disease or condition, such as depression or alcohol use disorder in a subject in need thereof.

This invention discloses a predictive model and its application for differentiating between alcohol use disorder (AUD) and alcoholic hepatitis (AH). By integrating the patient's basic clinical information, gut bacterial community characteristics, and gut fungal community structure, a multi-dimensional differentiation model is constructed. This model, through the joint analysis of gut microbiota (bacteria + fungi) and patient baseline data, provides an innovative and practical combination of molecular markers for the accurate differential diagnosis of AUD and AH.

Provided herein are methods of treating alcohol use disorder (AUD), opioid use disorder (OUD), and other substance use disorders (SUDs) in a subject, for example by administering an oral transmucosal dosage form of esketamine, such as an oral thin film (OTF) form of esketamine, sublingually or buccally. Disclosed methods may combine one or more therapy modalities provided before, during, and / or after drug administration. In some aspects, the methods comprise administering a dose of esketamine that is sufficient to produce dissociative effects in a subject. In some further aspects, the methods comprise the use of specific therapy modalities or ketamine-assisted psychotherapy (KAP) protocols, including manualized relapse prevention cognitive behavioral therapy (CBT). In yet further aspects, the methods comprise ongoing support, including additional psychotherapy and / or adjunct medication, such as naltrexone, buprenorphine, buprenorphine-naloxone, disulfiram, naloxone, and others.

The present disclosure relates to methods for treating a subject having a substance use disorder (SUD) with a 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 negative allosteric modulator. Specifically, in some embodiments, the present disclosure relates to methods for treating a subject having SUD at risk of relapse to alcohol use. In some embodiments, the present disclosure relates to methods for promoting remission in a subject having SUD. In some embodiments, the SUD is a stimulant use disorder such as alcohol use disorder (AUD), opioid use disorder (OUD), or cocaine use disorder (CUD).

The present invention relates to sulfamide derivatives of formula I, wherein the meaning of groups R1 and R2 is indicated in the description, for use to prevent and / or treat alcohol use disorder. The invention also relates to the administration of these derivatives in combination with other drugs and / or ligands. (I)

The disclosure provides a treatment for alcohol use disorder and related acetaldehyde toxicity, comprising repleting intracellular NAD+, and which may further comprise the administration of a GLP- 1 or dual GLP-1 / GIP receptor against.

Substituted chromen-2-one compounds, synthesized using computer-aided virtual screening in combination with structure-based drug design (SBDD), for inhibiting the enzymatic activity of alcohol dehydrogenase-2 (ALDH2) and liver-specific OATP1-dependent uptake, pharmaceutical compositions thereof, and methods of using the same for the treatment of alcohol use disorders (AUDs) are disclosed. In some embodiments, the inventive compounds inhibit liver-specific ALDH2 protein.

The disclosure is directed to, in part, compounds, or pharmaceutically acceptable salts or solvates thereof, for modulating the activity of aldehyde dehydrogenase such as ALDH2 and / or methods for treating and / or preventing an alcohol related disorder such as alcohol use disorder, alcohol induced disorder, alcohol abuse, alcohol dependence, alcohol intoxication, alcohol withdrawal, and the like and / or methods for reducing the amount of alcohol consumed, reducing alcoholic cravings, or increasing the percentage of no heavy drinking days for a subject with alcohol use disorder.

The present invention includes novel molecules and methods for using the same to treat Alcohol Use Disorder (AUD), Substance Use Disorder (SUD), tobacco use, pain, or proinflammatory disorders comprising: identifying a subject in need of treatment for at least one of AUD, SUD, pain, or a proinflammatory disorder; and providing the subject with an effective amount of a modified minocycline to ameliorate or eliminate the AUD, SUD, pain, or proinflammatory disorder and that has reduced, or no, antimicrobial activity, wherein the modified tetracycline has a formula, e.g., or the modified doxycycline, minocycline, and tigecycline and their tautomerized structures, where the R-groups shown in the minocycline example above could be different combination of halogen, acetyl ester, methyl ester, and diacetal.

The present invention relates to compounds according to formula (I), which are prodrugs of psychoactive lysergamides or its derivatives. The prodrugs provided herein exhibit improved pharmacokinetic properties during uptake as compared to LSD, as well as reduced side effects resulting from the metabolites thus formed. Due to the affinity of the active lysergamide compound, inter alia, for the 5-HT2A-receptor, these prodrugs are particularly advantageous for use in therapy, e.g., in the treatment of depression, posttraumatic stress disorder (PTSD), substance / alcohol use disorder (SUD / AUD).

Stress responses involve corticotropin releasing factor (CRF), the two cognate receptors (CRF1 and CRF2) and the CRF-binding protein (CRFBP). Utilizing a novel cell-based assay, a C-terminal CRFBP fragment [CRFBP(10 kD)] was found to potentiates CRF-intracellular Ca2+ release, demonstrating that CRFBP possesses excitatory roles in addition to the inhibitory role established by the N-terminal fragment of CRFBP [CRFBP(27 kD)]. This interaction was CRF2-specific, as CRF1 responses were not potentiated by CRFBP(10 kD). As there were currently no small molecule ligands available that selectively interact with either CRFBP or CRF2, a cell-based assay was miniaturized, wherein CRFBP(10 kD) was fused as a chimera with CRF2α, that allowed us to a perform a high-throughput screen (HTS) of approximately 350,000 small molecules. This resulted in the identification of negative allosteric modulators (NAMs) of the CRFBP(10 kD)-CRF2 complex that blunt CRF-induced potentiation of N-Methyl-D-aspartic acid receptor (NMDAR)-mediated synaptic transmission in dopamine neurons in the ventral tegmental area (VTA). These results provide the first evidence of specific roles for CRF2 and CRFBP in the modulation of neuronal activity and suggest that NMDARs in the VTA may be a target for the treatment of stress and substance abuse disorders such as alcohol use disorder.

This disclosure relates to methods for treating alcohol use disorder by administering to a human subject in need a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof. In certain embodiments, the compound is a compound of formula (II), (IIA), (IIB), or (IIC), or a solvate thereof, and is administered in a dose of from about 0.10 mg to about 10.0 mg. The disclosure also provides methods of preventing relapse to alcohol drinking, for reducing alcohol consumption, for decreasing alcohol craving, for maintenance of alcohol abstinence, for treating or preventing withdrawal from alcohol consumption, treating alcohol-related sleep disorder, and / or for reducing stress or anxiety level in a human subject.

The invention features methods for using 5-methoxy-N,N-dimethyltryptamine (5'MeO-DMT) in the treatment of substance use disorders (SUD), including specifically alcohol use disorder (AUD). Provided are specific therapeutically effective doses of 5-MeO-DMT which are well tolerated by patients and sufficient to induce a clinical response in the patient.

The invention relates to the technical field of medical information processing and health behavior intervention, and discloses an alcohol use disorder rehabilitation data processing system and method. A physiological monitoring terminal is deployed in the system, heart rate variability, galvanic conductance and skin temperature in a resting state are imported, and two-point calibration is performed to obtain an individual baseline; high-risk points are recorded, fences are arranged, and entering and exiting are judged according to the spherical distance; three parameters are collected regularly, channel availability and sample effectiveness are judged according to medical upper and lower limit normalization, and real-time deviation is calculated; summarizing according to natural days to generate a next-day individualized threshold value; when entering the fence and deviating from the over threshold, triggering the risk, calculating the intensity and performing four-stage grading; implementing micro intervention according to grades and recording; after intervention, a fixed window is used for re-measurement, and deviation, improvement and summarization are obtained; and performing seven-day statistical triggering and risk, aggregating daily average deviation and daily improvement, and generating a training duration and period report.

The disclosure relates to the field of alcohol use disorder. The disclosure provides methods of treating a subject having alcohol use disorder that includes administering ondansetron to a subject having a specified genotype corresponding to genetic variants that effect the 5-HT3 receptor complexes to which ondansetron binds and / or genetic variants that effect the expression of the serotonin transporter.

Disclosed are agents, compositions, and methods including valeric acid, or a pharmaceutically acceptable salt thereof or a derivative thereof, for treating or preventing alcohol use disorder or alcohol risk consumption.